Table 3.
Clinical characteristics of the total PSC patient series.
| UC group n = 35 |
Non-UC group n = 42 |
p value | |
|---|---|---|---|
| Gender, male : female | 17 : 18 | 18 : 24 | ns |
| Age at diagnosis of PSC, yrs | 36 ± 17 | 55 ± 19 | <0.0001 |
| Colonoscopy, yes : no | 35 : 0 | 20 : 22 | <0.0001 |
| Site of inflammation: | |||
| Intrahepatic bile duct | 8 | 7 | ns |
| Extrahepatic bile duct | 2 | 4 | ns |
| Both | 24 | 31 | ns |
| Child-Pugh classification (A/B/C) | 24/10/1 | 25/15/2 | ns |
| Liver biopsy Ludwig's stage: | |||
| Stage I | 2 | 0 | ns |
| Stage II | 17 | 21 | ns |
| Stage III | 3 | 5 | ns |
| Stage IV | 1 | 1 | ns |
| Unknown | 12 | 15 | ns |
| Treatment: | |||
| Ursodeoxycholic acid | 31 | 36 | ns |
| At PSC diagnosis: | |||
| PT, % | 88.7 ± 10.3 | 93.5 ± 11.6 | ns |
| CRP, mg/dl | 1.55 ± 2.48 | 1.69 ± 2.45 | ns |
| Alb, g/dl | 3.73 ± 0.45 | 3.73 ± 0.55 | ns |
| Total Bil, mg/dl | 0.77 ± 0.40 | 1.69 ± 2.06 | ns |
| AST, U/l | 39.6 ± 20.7 | 69.5 ± 62.1 | ns |
| ALT, U/l | 47.0 ± 25.8 | 75.8 ± 83.0 | ns |
| ALP, U/l | 935 ± 884 | 1060 ± 834 | ns |
| Cr, mg/dl | 0.69 ± 0.19 | 0.80 ± 0.33 | ns |
| Na, mEq/l | 140 ± 2 | 13 ± 3 | ns |
| PSC follow-up period (days) | 3254 (229-11825) | 1857 (173-9223) | 0.0133 |
Data are the mean ± SD, median (min-max), or the number of patients. Alb: albumin; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Bil: bilirubin; Cr: creatinine; CRP: C-reactive protein; Na: sodium; ns: not significant; PT: prothrombin time.